Nuvalent, Inc. Nuvalent, Inc.

Nuvalent, Inc.

NUVL

Rang în acțiuni #2095
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Preț acțiune
$123.96
Ultima sincronizare: 2026-07-21
Capitalizare de piață
$9.75B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
36.40%
Țară
US
Tranzacționează Nuvalent, Inc. (NUVL)

Categorie

Healthcare
Istoric al prețului acțiunii pentru Nuvalent, Inc. (NUVL)
Cel mai mare preț de închidere: $123.86 pe 2026-07-01

Cel mai mic preț de închidere: $18.50 pe 2021-07-01
Istoric al prețului acțiunii pentru Nuvalent, Inc. din 2021 până în 2026
Evoluția anuală a prețului acțiunii
An Performanță
2026 (TTM) 0.78%
2025 19.50%
2024 20.56%
2023 136.75%
2022 51.32%
2021 0.00%
Prețul acțiunii pentru companii similare sau concurente
Companie Preț acțiune Variație 1an% Țara
$528.84 24.01%
US
$237.25 783.61%
US
$137.83 -3.78%
AU
$891.40 9.49%
NL
$289.06 1.56%
BE